These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 24580032)

  • 1. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
    Brioli A; Melchor L; Cavo M; Morgan GJ
    Br J Haematol; 2014 May; 165(4):441-54. PubMed ID: 24580032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma.
    Hajek R; Okubote SA; Svachova H
    Br J Haematol; 2013 Dec; 163(5):551-64. PubMed ID: 24111932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance therapy in newly diagnosed multiple myeloma: current recommendations.
    Brioli A; Tacchetti P; Zamagni E; Cavo M
    Expert Rev Anticancer Ther; 2014 May; 14(5):581-94. PubMed ID: 24579569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
    Yuan J; Shah R; Kulharya A; Ustun C
    Leuk Res; 2010 Jul; 34(7):954-7. PubMed ID: 20138360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the clonal hierarchy in light-chain multiple myeloma: implications against the myeloma stem cell hypothesis.
    Pfeifer S; Perez-Andres M; Ludwig H; Sahota SS; Zojer N
    Leukemia; 2011 Jul; 25(7):1213-6. PubMed ID: 21494259
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug resistance in multiple myeloma: novel therapeutic targets within the malignant clone.
    Pilarski LM; Mant MJ; Belch AR
    Leuk Lymphoma; 1999 Jan; 32(3-4):199-210. PubMed ID: 10037018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.
    Issa ME; Takhsha FS; Chirumamilla CS; Perez-Novo C; Vanden Berghe W; Cuendet M
    Clin Epigenetics; 2017; 9():17. PubMed ID: 28203307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings.
    Richardson PG; Laubach J; Mitsiades CS; Schlossman R; Hideshima T; Redman K; Chauhan D; Ghobrial IM; Munshi N; Anderson KC
    Br J Haematol; 2011 Sep; 154(6):755-62. PubMed ID: 21732930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonal evolution of one rare case of multiple myeloma with bilateral testicular mass as initial presentation.
    Lin N; Wu Y; Liang Y; Mo W; Li Y; Zhang R
    Ann Hematol; 2020 Feb; 99(2):377-378. PubMed ID: 31879789
    [No Abstract]   [Full Text] [Related]  

  • 10. Getting to the root of the problem: the causes of relapse in multiple myeloma.
    Chan Chung KC; Tiedemann RE
    Expert Rev Anticancer Ther; 2014 Mar; 14(3):251-4. PubMed ID: 24397833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibition and multiple myeloma.
    Kanagasabaphy P; Morgan GJ; Davies FE
    Curr Opin Investig Drugs; 2007 Jun; 8(6):447-51. PubMed ID: 17621873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance therapy in multiple myeloma.
    Mihelic R; Kaufman JL; Lonial S
    Leukemia; 2007 Jun; 21(6):1150-7. PubMed ID: 17344913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotype-structured model of intra-clonal heterogeneity and drug resistance in multiple myeloma.
    Bouchnita A; Volpert V
    J Theor Biol; 2024 Jan; 576():111652. PubMed ID: 37952610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple myeloma with extramedullary disease.
    Oriol A
    Adv Ther; 2011 Nov; 28 Suppl 7():1-6. PubMed ID: 22105527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukemia relapse reconsidered from the molecular aspect.
    Naoe T; Nakano Y; Kiyoi H
    Leuk Lymphoma; 2000 May; 37(5-6):527-34. PubMed ID: 11042512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Centrosome amplification and clonal evolution in multiple myeloma: Short review.
    Kryukova E; Kryukov F; Hajek R
    Crit Rev Oncol Hematol; 2016 Feb; 98():116-21. PubMed ID: 26589397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel agents and the paradigm of continuous treatment in multiple myeloma.
    Palumbo A
    Leuk Res; 2012 Nov; 36 Suppl 1():S1-2. PubMed ID: 23176718
    [No Abstract]   [Full Text] [Related]  

  • 19. Extramedullary plasmacytomas in the context of multiple myeloma.
    Aguado B; Iñigo B; Sastre JL; Oriol A
    Adv Ther; 2011 Nov; 28 Suppl 7():7-13. PubMed ID: 22105528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common progenitor cells in mature B-cell malignancies: implications for therapy.
    Green MR; Alizadeh AA
    Curr Opin Hematol; 2014 Jul; 21(4):333-40. PubMed ID: 24811163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.